Tirzepatide: research

A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.

Also called: Mounjaro, Zepbound, LY3298176, LY-3298176, Tirz.

GLP-1 / GIP / glucagon agonists · Dual GIP and GLP-1 receptor agonist · Evidence: Approved drug.

216 date-filtered interventional registry records name tirzepatide; 71 are completed and 46 have posted results. This is a registry inventory, not 216 completed efficacy trials.

Studies

Tirzepatide dosage

Typical reported dose: 2.5 mg once a week to start, up to 15 mg

  • First human study: single 0.25 mg: 0.25 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
  • First human study: single 0.5 mg: 0.5 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
  • First human study: single 1 mg: 1 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
  • First human study: single 2.5 mg: 2.5 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
  • First human study: single 5 mg: 5 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
  • First human study: single 8 mg: 8 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Tirzepatide side effects and risks

Reported side effects

  • Nausea: 5/10/15 mg: 25/29/28%; placebo 8%., moderate. Review fluids and food intake; contact the prescriber if persistent or severe. (source)
  • Diarrhea: 5/10/15 mg: 19/21/23%; placebo 8%., moderate. Review fluids and food intake; contact the prescriber if persistent or severe. (source)
  • Constipation: 5/10/15 mg: 17/14/11%; placebo 5%., moderate. Review fluids and food intake; contact the prescriber if persistent or severe. (source)
  • Vomiting: 5/10/15 mg: 8/11/13%; placebo 2%., moderate. Persistent vomiting or inability to drink needs prompt care. (source)
  • Stomach pain: 5/10/15 mg: 9/9/10%; placebo 5%., mild (source)
  • Indigestion: 5/10/15 mg: 9/9/10%; placebo 4%., mild (source)
  • Injection-site reaction: 5/10/15 mg: 6/8/8%; placebo 2%., mild (source)
  • Fatigue: 5/10/15 mg: 5/6/7%; placebo 3%., mild (source)
  • Hair loss: 5/10/15 mg: 5/4/5%; placebo 1%., mild (source)
  • Reflux: 5/10/15 mg: 4/4/5%; placebo 2%., mild (source)
  • Burping: 5/10/15 mg: 4/5/5%; placebo 1%., mild (source)
  • Gas or bloating: 5/10/15 mg: 3/3/4%; placebo 2%., mild (source)
  • Dizziness: 5/10/15 mg: 4/5/4%; placebo 2%., mild (source)
  • Low blood pressure: 5/10/15 mg: 1/1/2%; placebo 0%., moderate (source)

Stop and get help if

  • Severe, persistent belly pain, especially reaching the back: Stop dosing and get urgent medical assessment for pancreatitis.
  • Swollen tongue or throat, trouble breathing, collapse: Call emergency services now; do not take another dose.
  • Upper-right belly pain with fever or yellow skin: Get urgent care for possible gallbladder or bile-duct disease.
  • Ongoing vomiting, very little urine, inability to keep fluids down: Get urgent assessment for dehydration and kidney injury.
  • Severe bloating with vomiting and no stool or gas: Get urgent care for possible bowel blockage.
  • Confusion, seizure, fainting or low glucose that does not resolve: Get emergency help; severe low blood sugar needs prompt treatment.
  • Sudden loss of vision or new major vision change: Get urgent eye assessment the same day.
  • Chest pain, collapse or severe shortness of breath: Call emergency services now.
  • New neck lump, trouble swallowing or persistent hoarseness: Arrange prompt medical assessment.

Who should avoid it

  • pregnant: Stop weight-loss use when pregnancy is recognized; human safety data are inadequate and animal studies found fetal harm.
  • tryingToConceive: UK guidance says stop at least 1 month before a planned pregnancy.
  • breastfeeding: A single-dose study found low milk transfer, but infant effects and repeated dosing remain unknown.
  • under18: Mounjaro is licensed from age 10 for type 2 diabetes; that does not authorize pediatric weight-loss use.
  • mtcOrMen2: Formal US contraindication: personal or family medullary thyroid cancer, or MEN2.
  • other: Do not use after a serious allergy to tirzepatide or an ingredient.
  • eatingDisorderHistory: Screen for restrictive intake, bingeing and nutritional harm.
  • pancreatitisHistory: Review prior pancreatitis. Stop for suspected pancreatitis; NICE says do not restart after confirmed pancreatitis.
  • gallbladderDisease: Gallstones and gallbladder inflammation can occur, especially with weight reduction.
  • gastroparesis: Not recommended with severe delayed stomach emptying; review persistent vomiting or severe constipation before dosing.
  • kidneyDisease: No label dose adjustment, including dialysis. Vomiting or diarrhea can still cause dehydration and kidney injury.
  • liverDisease: No label dose adjustment is required. Advanced illness and poor intake still need individualized review.
  • diabeticRetinopathy: Rapid glucose improvement can briefly worsen eye disease. Monitor existing retinopathy and new vision symptoms.
  • diabetes: Review glucose-lowering medicines and monitor sugar. Type 1 diabetes still requires insulin.
  • heartCondition: Review fluid status, dizziness and blood pressure medicines; heart-failure evidence is specific to obesity with preserved ejection fraction.
  • surgeryPlanned: Tell the anesthesia team; slowed stomach emptying can leave food in the stomach despite fasting. Plan dosing and fasting together.
  • testedAthlete: Markers of tirzepatide are monitored in and out of competition in 2026. Monitoring is not prohibition.

Interactions

  • Insulin: Low blood sugar risk rises. Insulin doses may need clinician-led adjustment; never simply stop insulin in type 1 diabetes.
  • Sulfonylureas and other insulin secretagogues: Low blood sugar becomes more likely; the prescriber may reduce the secretagogue dose.
  • Oral hormonal contraception: Use non-oral contraception or add a barrier for 4 weeks after starting and after each dose increase; stomach emptying changes absorption.
  • Narrow-window oral medicines, including warfarin: Delayed stomach emptying can alter absorption. Review effect or drug levels; check INR when clinically indicated for warfarin.
  • Other oral medicines: Review medicines that need a threshold concentration for effect. Absorption may change, especially after starting or increasing the dose.
  • Another tirzepatide product or GLP-1 drug: Zepbound labeling advises against another tirzepatide product or GLP-1 drug. Overlapping effects can worsen vomiting and low intake.
  • Amylin-type appetite drugs: Extra appetite suppression and vomiting are concerns. A controlled research combination does not validate a home-mixed stack.
  • Diuretics and blood pressure medicines: This is a fluid and blood-pressure concern, not a proven direct drug interaction. Poor intake or diarrhea can worsen dizziness and dehydration.
  • DPP-4 inhibitors: NICE guidance advises against combining DPP-4 inhibitors with tirzepatide because they act on the same pathway.

Product quality risks

  • FDA reports fraudulent compounded-product labels, dosing errors and unapproved online products; counterfeit packaging can mislead.
  • A 2026 analysis found a tirzepatide/B12 reaction impurity; clinical effects remain unknown.
  • A purity percentage does not establish the correct dose, identity, sterility or endotoxin level.
  • Poison-center data include serious outcomes, but class-wide reports do not give a tirzepatide user’s risk.

How Tirzepatide works

It activates two gut-hormone receptors, GIP and GLP-1. This helps the pancreas release insulin when glucose is high, reduces appetite and slows stomach emptying. It does not activate the glucagon receptor.

  • GIP receptor: Supports glucose-dependent insulin release and contributes to the combined effect.
  • GLP-1 receptor: Supports insulin release, lowers glucagon, slows stomach emptying and helps reduce food intake.

Half-life: About 5 days

Gaps: Long-term wellness microdosing, split doses and cycling have no verified outcome trial here; early 0.5–1 mg exposure is not proof of these claims. Higher-dose NCT06037252 hides numeric doses. 15 mg is the highest fully disclosed repeat-dose regimen extracted; an absolute human ceiling cannot be certified. Above-label 17.5 mg reports are retained in community only; no ceiling-tagged protocol is created because masked higher doses may already be studied. No safe or effective tirzepatide–semaglutide, tirzepatide–retatrutide or tirzepatide–cagrilintide home stack was established. Infant outcomes, repeated-dose milk transfer, pregnancy safety and rare long-latency harms remain uncertain. Online powder stability, sterility and market-wide underdosing rates are not established; semaglutide test-buy numbers cannot be assigned to tirzepatide. Most pivotal studies were manufacturer-funded; independent data and underrepresented populations remain limited. Some arm-level adverse-event rates and early cohort details were unavailable in accessible abstracts; no missing number was inferred. FDA found no increased suicidal-behavior signal in its 2026 review and requested warning removal; this does not replace assessment of new severe mood symptoms.

Related to Tirzepatide

Tirzepatide: the short version

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.